Sydney (AFP) – Australian airline Qantas said Monday it will launch the world’s first direct commercial flights linking Sydney, London and New York by the end of 2025, putting aircraft maker Airbus on a multi-billion dollar order. The company said in a statement that it will purchase 12 Airbus A350-1000s to secure flights within a project called Project Sunrise, to cities such as London and New York from Sydney, by the end of 2025. According to the price specified in the 2018 guide. In the last year that Airbus published prices for its planes, the A350-1000 was priced at $366.5 million. However, this price does not reflect the actual amount paid by the airlines, as the negotiations allow to reduce prices, especially for large orders. Thanks to the A350 and Project Sunrise, Qantas CEO Alan Joyce said, according to the statement, that “each city is only one flight away from Australia.” Qantas conducted extended test flights in 2019, including a 17,750 km journey between London and Sydney that lasted 19 hours and 19 minutes. In the same year, a test flight between New York and Sydney, which stretched over 16,200 km, took a little more than 19 hours. Singapore Airlines currently operates the world’s longest non-stop commercial flight between Singapore and New York, lasting approximately 19 hours. To date, the longest direct flight operated by Qantas connects Darwin in northern Australia with London, extending approximately 14,000 km and taking 17 hours and 55 minutes. Initially this flight was from Perth in the west of the country, but it has been moved to Darwin due to restrictions related to COVID-19 in Australia. The company announced that it will resume the flight between Perth and London this year. “As you would expect, the aircraft is specially designed to ensure maximum comfort for long-distance flights,” said Joyce. The company announced that the new A350 aircraft will be designed to carry 238 passengers in total, and the first class offers a separate bed, a reclining seat and a locker. The company promises that the seats in the economy classes will be wider, in addition to a space designated for “moving”.
Daily Archives
May 2, 2022
In its daily bulletin on the epidemiological situation, the ministry also specified that the number of first-timers reached 24,806,427, that of people who received two doses amounted to 23,285,210, while 6,255,664 people received had three injections of the vaccine.
The new infection report brings the total number of contaminations since the first case reported in Morocco on March 02, 2020 to 1,164,984, while the number of recovered people has increased to 1,148,556, i.e. a recovery rate of 98, 6%.
The new cases of infection have been identified in the regions of Rabat-Salé-Kénitra (04), Casablanca-Settat (03), Marrakech-Safi (3) and Tanger-Tétouan-Al Hoceima (1).
The total number of deaths is still 16,069 (lethality 1.4%), with zero cases recorded in the last 24 hours.
Active cases number 359 while no severe or critical cases have been recorded in the past 24 hours, for a total of 11.
As for the occupancy rate of intensive care beds, it is 0.2%.
FDA Approves Upadacitinib as Oral Treatment for Adults With Ankylosing Spondylitis
written by Alexandra Hartman Editor-in-Chief
The approval of a new drug is welcome news for our patient community.
Spinal image of a patient with ankylosing spondylitis. Details: Shutterstock.
“The ankylosing spondylitis it is a debilitating disease that often strikes younger adults and over time can cause lasting structural damage that can have an emotional effect on a patient’s life,” said Thomas Hudson, senior vice president, research and development, AbbVie’s chief scientific officer.
“This latest approval demonstrates another important step forward in our mission to advance standards of care for rheumatic diseases,” he said in the statement.
The approval of the FDA in AD is supported by safety and efficacy data from the phase 3 clinical study, SELECT-AXIS 2 (Study 1) that evaluated RINVOQ in patients who had had an inadequate response or intolerance to one or two disease-modifying antirheumatic drugs ( MAME) and the phase 2/3 clinical study, SELECT-AXIS 1, which evaluated RINVOQ in patients who had never received a biologic MAME and had had an inadequate response or intolerance to at least two nonsteroidal anti-inflammatory drugs (NSAIDs)1 -3.
“Many patients with ankylosing spondylitis do not achieve disease control with current biologic therapies, and additional treatments are needed to help alleviate the signs and symptoms of this disease,” said Atul Deodhar, professor of medicine and medical director of Rheumatology Clinics for the Division of Arthritis and Rheumatic Diseases at Oregon Health & Science University, and investigator of the SELECT-AXIS 1 study.
“With the approval of the FDA Today, patients who do not respond to a TNF inhibitor have an additional oral treatment option in conjunction with their rheumatologist to help take control of this disease,” the news release reveals.
In both the SELECT-AXIS 1 and SELECT-AXIS 2 clinical studies, a significantly higher proportion of patients receiving RINVOQ 15 mg achieved an ASAS40* response, the primary endpoint, (51% and 44.5%, respectively) compared to placebo (26% and 18.2%, respectively) at week 14. Clinical responses were observed as early as week 4 in the SELECT-AXIS study for ASAS401-3 values.
“Currently, treatment options are limited for people living with ankylosing spondylitisparticularly when pain symptoms persist despite the use of TNF blocker therapy,” said Cassie Shafer, chief executive officer, Spondylitis Association of America (SAA).
“The approval of a new drug is welcome news for our patient community, offering them the potential to help more people find meaningful relief from AD symptoms and help them reach their treatment goals,” said Shafer.
La Villa 7 – Flo is very jealous of Charlotte’s ex – La Villa des Cœurs Brisés
written by Alexandra Hartman Editor-in-Chief
Ex week starts strong for Charlotte and Belle. After the announcement of this special week, the two young women are immediately summoned to go on a date with their exes. Upon their return, Flo is very tense, he does not appreciate at all that Charlotte is happy to have gone on a date with her ex. The two bachelors are not officially together, but it seems that Flo begins to develop feelings of jealousy when Charlotte dates other boys. Excerpt from The Villa of Broken Hearts. Season 07 Episode 27.